-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.↓
JPYBörse Japan Exchange Group Tokio-
JPYSankyo Co LtdBörse Japan Exchange Group Tokio
-
SANKYO CO LTDBörse Gettex System der Börse MünchenEURSymbol SOK
-
SANKYO CO LTDBörse Börse FrankfurtEURSymbol SOK
-
SANKYO CO LTDBörse Börse MünchenEURSymbol SOK
-
SANKYO CO LTDBörse Börse StuttgartEURSymbol SOK
-
USDSankyo Co LtdBörse Amerikanscher Freiverkehr OTC oder "Pink Sheets"
-
USD
-
JPY
-
Marktkapitalisierung
1.519.000.000
Mitarbeiter
906
Zahlte zuletzt am 30.03.2021 eine Dividende von 75 . Seit damals wurde keine Dividende mehr ausgeschüttet Übersicht
Dir gefallen die Informationen zu Sankyo Co Ltd?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Zur ING Diba
Dir gefallen die Informationen zu Sankyo Co Ltd?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Zu Trade Republic
Dir gefallen die Informationen zu Sankyo Co Ltd?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
Zu BUX Zero
Dir gefallen die Informationen zu Sankyo Co Ltd?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
Zur Comdirect
4 News & Informationen zur Sankyo Co Ltd Aktie
Diabetic Peripheral Neuropathy Pipeline Assessment 2020: Therapeutic Analysis Report Featuring 20+ Companies & 15+ Drug Profiles
Diabetic Peripheral Neuropathy Pipeline Report helps in identifying emerging players in the market and their portfolios. The global Diabetic Peripheral Neuropathy therapeutic landscape evaluates based on mechanism of action (MoA), route of administration (RoA), phases of development, and molecule type.Los Angeles, USA, Jan. 14, 2021 (GLOBE NEWSWIRE) — Diabetic Peripheral Neuropathy Pipeline Assessment 2020: Therapeutic Analysis Report Featuring 20+ Companies & 15+ Drug Profiles Diabetic Peripheral Neuropathy Pipeline Report helps in identifying emerging players in the market and their portfolios. The global Diabetic Peripheral Neuropathy therapeutic landscape evaluates based on mechanism of action (MoA), route of administration (RoA), phases of development, and molecule type. “Diabetic Peripheral Neuropathy Pipeline Analysis” by DelveInsight features the details around the Diabetic Peripheral Neuropathy pipeline landscape, unmet needs, and Diabetic Peripheral Neuropathy therapeutic assessment of the key pipeline therapies. Some of the chief Diabetic Peripheral Neuropathy Pipeline Highlights * 20+ key companies are working to strengthen the Diabetic Peripheral Neuropathy pipeline including the Regenacy Pharmaceuticals LLC, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Pure Green, and several others. * Diabetic Peripheral Neuropathy market presents promising and a vast new product pipeline with pivotal trials, NME Projects and phase-advancing therapeutic candidates. * 15+ Pipeline therapies in different states of clinical development. Pipeline drugs profiled in the report include Ricolinostat, FE-SYHA1402, etc. * Collaborations and Deals * Pipeline Drug Profiles provided include: * Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others. * Phases of development of Diabetic Peripheral Neuropathy Drugs * Mechanism of Action * Route of Administration * Diabetic Peripheral Neuropathy Companies involved including originator, licensing companies, developer, investors, and others * New molecular entity details * Drug designations and other special status provided by regulatory authorities * Diabetic Peripheral Neuropathy Market Drivers and Barriers * Diabetic Peripheral Neuropathy Therapeutics Market LandscapeRequest for Diabetic Peripheral Neuropathy Pipeline Assessment Sample ReportDiabetic Neuropathy is nerve damage caused by diabetes. When it affects the arms, hands, legs, and feet, it is known as Diabetic Peripheral Neuropathy. Diabetic Peripheral Neuropathy pipeline report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical, and discovery. Diabetic Peripheral Neuropathy Emerging Drugs * FE-SYHA1402 by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.ZhongQi Pharmaceutical Technology is conducting a multiple doses study to assess the safety, tolerability, pharmacokinetics of SYHA1402 in healthy candidates. This study comprises two parts: The objective of the food effect study (Part 1) is to evaluate the effect of food on the pharmacokinetic profiles of SYHA1402 tablets under fed and fasted conditions following the oral administration of SYHA1402. The aim of the multiple doses study (Part 2) is to examine the safety, tolerability, and Pharmacokinetics of SYHA1402 in healthy subjects following oral administration of multiple rising doses. Secondary objectives are the exploration of pharmacokinetics (PK) following multiple oral doses. * VM202 by HelixmithVM202 (donaperminogene seltoplasmid) is a first-in-class, proprietary, non-viral, potentially regenerative plasmid DNA gene therapy. VM202 is a novel genomic cDNA hybrid human hepatocyte growth factor (HGF) gene with a novel and proprietary coding sequence (HGF-X7) expressing two isoforms – a configuration that closely mimics HGF productions in humans that is required for optimal therapeutic benefits. Because there is no change in the coding region of the HGF gene, HGF proteins generated from VM202 are identical to wild-type human HGF proteins. * NYX-2925 by AptinyxNYX-2925 is a novel, oral small molecule NMDA receptor modulator in development for chronic pain treatment. Dysregulation of glutamatergic circuits in the brain is required in the development of centralized chronic pain. NYX-2925 is in late-stage clinical development across two chronic pain indications -Painful Diabetic Peripheral Neuropathy and Fibromyalgia. * LX9211 by Lexicon PharmaceuticalsLX9211 is a potent, orally delivered, selective small-molecule inhibitor of AAK1, a target discovered and extensively characterized in an alliance with Bristol Myers Squibb. Preclinical data displayed central nervous system penetration and lessen in pain behaviour in models of neuropathic pain. Lexicon has exclusive research, development, and commercialization rights to LX9211 and additional compounds acting through AAK1.For further product profiles, request @ Diabetic Peripheral Neuropathy Pipeline Analysis Sample ReportScope of Diabetic Peripheral Neuropathy Drug Pipeline Report * Coverage: Global * Major Players: 20+ Key Companies * Diabetic Peripheral Neuropathy Prominent Players: Regenacy Pharmaceuticals LLC, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Pure Green, Helixmith Co., Ltd., Bayer, Aptinyx, Eliem Therapeutics (UK) Ltd., Lexicon Pharmaceuticals, WinSanTor, Inc, Haisco Pharmaceutical Group Co., Ltd., Eli Lilly and Company, Daiichi Sankyo Co., Ltd., Avazzia, Inc, POLYSAN Scientific & Technological Pharmaceutical Company, Achelios Therapeutics Inc, Applied Therapeutics, Bionevia Pharmaceuticals, Regenacy Pharmaceuticals, Commence Bio Inc, Grunenthal GmbH, Immune Pharmaceuticals, and many others. * Key Drugs Profiles: 15+ Products * Diabetic Peripheral Neuropathy Drugs Profiles: Ricolinostat, FE-SYHA1402, CBD, Engensis, BAY1817080, NYX-2925 50, ETX-018810, LX9211, WST-057 (4% pirenzepine), HSK16149, LY3016859, Mirogabalin, Electrical Stimulation, Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid), AT 001, BNV-222, Amitriptyline/ketamine, and many others. * Phases: * Diabetic Peripheral Neuropathy Therapies Late-stage (Phase III) * Diabetic Peripheral Neuropathy Therapies (Phase II) * Diabetic Peripheral Neuropathy Therapies (Phase I) * Diabetic Peripheral Neuropathy Therapies Pre-clinical stage and Discovery candidates * Discontinued and Inactive candidates * Molecule Types: * Small molecule * Gene Therapies * Route of Administration: * Infusion * Intradermal * Intramuscular * Intranasal * Intravaginal * Oral * Parenteral * Subcutaneous * Topical * Product Types: * Mono * Combination * Mono/Combination Key Questions regarding Current Diabetic Peripheral Neuropathy Drug Treatment Landscape and Emerging Therapies Answered in the Pipeline Report * What are the current options for Diabetic Peripheral Neuropathy treatment? * How many companies are developing therapies for the treatment of Diabetic Peripheral Neuropathy? * How many Diabetic Peripheral Neuropathy emerging therapies are in the early-stage, mid-stage, and late stages of development for the treatment of Diabetic Peripheral Neuropathy? * What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact the Diabetic Peripheral Neuropathy market? * Which are the dormant and discontinued products and the reasons for the same? * What is the unmet need for current therapies for the treatment of Diabetic Peripheral Neuropathy? * What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing Diabetic Peripheral Neuropathy therapies? * What are the key designations that have been granted for the emerging therapies for Diabetic Peripheral Neuropathy? * How many patents are granted and pending for the emerging therapies for the treatment of Diabetic Peripheral Neuropathy? Table of Contents 1Introduction 2Executive Summary of Diabetic Peripheral Neuropathy 3Diabetic Peripheral Neuropathy Overview 4Diabetic Peripheral Neuropathy Pipeline Therapeutics 5Diabetic Peripheral Neuropathy Therapeutic Assessment 6Diabetic Peripheral Neuropathy – DelveInsight’s Analytical Perspective 7Diabetic Peripheral Neuropathy Late Stage Products (Phase III) 7.1Engensis: Helixmith Co., Ltd. 8Diabetic Peripheral Neuropathy Mid Stage Products (Phase II) 8.1Aptinyx: NYX-2925 8.2LX9211: Lexicon Pharmaceuticals 9Diabetic Peripheral Neuropathy Early Stage Products (Phase I) 9.1FE-SYHA1402: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 9.2SR419: SIMR (Australia) Biotech Pty Ltd. 10Diabetic Peripheral Neuropathy Pre-clinical and Discovery Stage Products 11Diabetic Peripheral Neuropathy Inactive Products 12Diabetic Peripheral Neuropathy Comparative Analysis 13Diabetic Peripheral Neuropathy Key Companies 14Diabetic Peripheral Neuropathy Key Products 15Company-University Collaborations (Licensing/Partnering) Analysis 16Diabetic Peripheral Neuropathy Unmet Needs 17Diabetic Peripheral Neuropathy Market Drivers and Barriers 18Diabetic Peripheral Neuropathy- Future Perspectives and Conclusion 19Diabetic Peripheral Neuropathy Analyst Views 20Appendix Browse Detailed TOC, Emerging Drugs and Key Companies @ Diabetic Peripheral Neuropathy Pipeline Analysis ReportRelated Reports * Diabetic Peripheral Neuropathy Market Analysis DelveInsight's Diabetic Peripheral Neuropathy Market Insights, Epidemiology, and Market Forecast – 2030 report provides an in-depth understanding of historical and forecasted epidemiology. * Diabetic Peripheral Neuropathy Epidemiology Forecast Analysis DelveInsight’s ‘Diabetic Peripheral Neuropathy Epidemiology Forecast-2030’ report delivers an in-depth understanding of the disease, historical, forecasted epidemiology trends of DPN in 7MM. * Dementia with Diabetes Market Analysis DelveInsight's Dementia with Diabetes Market Insights, Epidemiology, and Market Forecast – 2030 report provides an in-depth understanding of historical and forecasted epidemiology. * Diabetic Foot Market Analysis DelveInsight's Diabetic Foot Market Insights, Epidemiology and Market Forecast – 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology. * Diabetic Gastroparesis Market Analysis DelveInsight's Diabetic Gastroparesis Market Research Report presents a detailed analysis of the market listing Diabetic Gastroparesis Epidemiology, Drug therapies, market trends in 7MM. * Diabetic Kidney Disease Market Analysis DelveInsight's Diabetic Kidney Disease (DKD) Market Insights, Epidemiology, and Market Forecast – 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology. * Diabetes Market Analysis DelveInsight's Diabetes Market Insights, Epidemiology, and Market Forecast – 2030 report provides thorough insights on epidemiology and market trends.About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. CONTACT: Contact Us: Shruti Thakur info@delveinsight.com +1(919)321-6187 http://www.delveinsight.com
Diabetic Peripheral Neuropathy Pipeline Assessment 2020: Therapeutic Analysis Report Featuring 20+ Companies & 15+ Drug Profiles
Los Angeles, USA, Jan. 14, 2021 (GLOBE NEWSWIRE) — Diabetic Peripheral Neuropathy Pipeline Assessment 2020: Therapeutic Analysis Report Featuring 20+ …
Japanese shares fall as PM Suga considers state of emergency for Tokyo
International Business News: Japanese shares fell on Monday after Prime Minister Yoshihide Suga said he is considering a state of emergency for Tokyo and surrounding prefectures t
Japan stocks start year in red as Tokyo braces for state of emergency
Japanese shares ended lower on
Monday after Prime Minister Yoshihide Suga said he is
considering a state of emergency for Tokyo and surrounding
prefectures to contain a spike in local coronavirus… | January 4, 2021